Atea Pharmaceuticals

AVIRNASDAQ
$3.43
0.061.78%
At Close: -
$3.43
00.00%
After Hours: Jul 12, 4:00 PM EDT
15 minutes delayed
Consensus Rating1
Market Perform
Highest Price Target1
$6.00
Lowest Price Target1
$4.00
Consensus Price Target1
$5.00

Atea Pharmaceuticals (NASDAQ:AVIR) Stock, Analyst Ratings, Price Targets, Forecasts

Atea Pharmaceuticals Inc has a consensus price target of $5 based on the ratings of 3 analysts. The high is $6 issued by SVB Leerink on January 27, 2023. The low is $4 issued by Morgan Stanley on January 24, 2023. The 3 most-recent analyst ratings were released by JP Morgan, SVB Leerink, and Morgan Stanley on March 16, 2023, January 27, 2023, and January 24, 2023, respectively. With an average price target of $6 between JP Morgan, SVB Leerink, and Morgan Stanley, there's an implied 74.93% upside for Atea Pharmaceuticals Inc from these most-recent analyst ratings.

Analyst Rating and Forecast
12345
1.3
Strong Sell
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

SVB Leerink
Morgan Stanley

1calculated from analyst ratings

Analyst Ratings for Atea Pharmaceuticals

Buy NowGet Alert
08/10/2023Buy NowJP Morgan
Eric Joseph
DowngradeNeutral → UnderweightGet Alert
03/16/2023Buy Now133.24%JP Morgan
Eric Joseph
$12 → $8MaintainsNeutralGet Alert
01/27/2023Buy Now74.93%SVB Leerink
Roanna Ruiz
$8 → $6MaintainsMarket PerformGet Alert
01/24/2023Buy Now16.62%Morgan Stanley
Matthew Harrison
$7 → $4MaintainsUnderweightGet Alert
08/15/2022Buy Now104.08%Morgan Stanley
Matthew Harrison
$6 → $7MaintainsUnderweightGet Alert
03/02/2022Buy Now133.24%JP Morgan
Eric Joseph
$10 → $8MaintainsNeutralGet Alert
03/01/2022Buy Now162.39%SVB Leerink
Roanna Ruiz
$10 → $9MaintainsMarket PerformGet Alert
02/16/2022Buy Now191.55%SVB Leerink
Roanna Ruiz
$11 → $10MaintainsMarket PerformGet Alert
01/06/2022Buy Now104.08%Morgan Stanley
Matthew Harrison
$14 → $7DowngradeEqual-Weight → UnderweightGet Alert
11/18/2021Buy Now220.7%SVB Leerink
Roanna Ruiz
DowngradeOutperform → Market PerformGet Alert
10/20/2021Buy Now483.09%SVB Leerink
Roanna Ruiz
MaintainsOutperformGet Alert
10/20/2021Buy Now366.47%JP Morgan
Eric Joseph
DowngradeOverweight → NeutralGet Alert
10/05/2021Buy Now1503.5%Morgan Stanley
Matthew Harrison
DowngradeOverweight → Equal-WeightGet Alert
09/09/2021Buy Now1649.27%SVB Leerink
Roanna Ruiz
Initiates → OutperformGet Alert
08/18/2021Buy Now978.72%Morgan Stanley
Matthew Harrison
MaintainsOverweightGet Alert

FAQ

Q

What is the target price for Atea Pharmaceuticals (AVIR) stock?

A

The latest price target for Atea Pharmaceuticals (NASDAQ:AVIR) was reported by JP Morgan on August 10, 2023. The analyst firm set a price target for $0.00 expecting AVIR to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Atea Pharmaceuticals (AVIR)?

A

The latest analyst rating for Atea Pharmaceuticals (NASDAQ:AVIR) was provided by JP Morgan, and Atea Pharmaceuticals downgraded their underweight rating.

Q

When was the last upgrade for Atea Pharmaceuticals (AVIR)?

A

There is no last upgrade for Atea Pharmaceuticals

Q

When was the last downgrade for Atea Pharmaceuticals (AVIR)?

A

The last downgrade for Atea Pharmaceuticals Inc happened on August 10, 2023 when JP Morgan changed their price target from N/A to N/A for Atea Pharmaceuticals Inc.

Q

When is the next analyst rating going to be posted or updated for Atea Pharmaceuticals (AVIR)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atea Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atea Pharmaceuticals was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.

Q

Is the Analyst Rating Atea Pharmaceuticals (AVIR) correct?

A

While ratings are subjective and will change, the latest Atea Pharmaceuticals (AVIR) rating was a downgraded with a price target of $0.00 to $0.00. The current price Atea Pharmaceuticals (AVIR) is trading at is $3.43, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch